Dark Forest Capital Management LP Buys New Shares in Illumina, Inc. (NASDAQ:ILMN)

Dark Forest Capital Management LP bought a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 5,151 shares of the life sciences company's stock, valued at approximately $688,000.

Several other large investors have also modified their holdings of the stock. Golden State Wealth Management LLC acquired a new position in shares of Illumina in the 4th quarter valued at about $32,000. Versant Capital Management Inc increased its position in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after purchasing an additional 146 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Illumina in the 4th quarter valued at approximately $45,000. Assetmark Inc. lifted its holdings in Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after acquiring an additional 296 shares during the last quarter. Finally, Lee Danner & Bass Inc. acquired a new position in shares of Illumina during the fourth quarter valued at $48,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Canaccord Genuity Group decreased their target price on shares of Illumina from $115.00 to $92.00 and set a "hold" rating for the company in a research report on Tuesday. HSBC cut shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 target price for the company. in a research note on Friday, February 28th. Hsbc Global Res lowered Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Morgan Stanley lowered their price target on Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada dropped their target price on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $137.55.

Illumina Trading Down 0.5 %

Illumina stock traded down $0.38 during midday trading on Wednesday, hitting $76.72. 286,651 shares of the stock were exchanged, compared to its average volume of 2,276,264. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $12.14 billion, a PE ratio of -9.97, a P/E/G ratio of 1.60 and a beta of 1.38. The company has a fifty day simple moving average of $81.11 and a two-hundred day simple moving average of $117.11.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.